ClinicalTrials.gg
RecruitingNCT07606755Updated Nov 18, 2026

Clinical Efficacy Study of Jinfeng Pill in the Treatment of Perimenopausal Syndrome

A Phase 4 interventional study of Jinfeng Pill and Placebo in Perimenopausal Syndrome, sponsored by Tongji Hospital. Recruiting at 3 sites in China. Open to female participants aged 45 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Tongji Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
45 Years to 55 Years
Sex
Female
01

Study summary

Perimenopausal syndrome (PMS) is a common condition affecting women during the transition to menopause, often causing hot flashes, sweating, insomnia, anxiety, depression, fatigue, and reduced quality of life. Current hormone replacement therapy can improve symptoms, but long-term use may increase the risk of breast cancer and cardiovascular complications. Therefore, safer and more effective alternative treatments are needed.

Jinfeng Pill is a traditional Chinese medicine patented drug that has been widely used in gynecological disorders. Previous studies suggest that it may help regulate hormone balance, improve ovarian function, and reduce inflammation. Recent research has also shown that intestinal bacteria ("gut microbiota") may influence estrogen metabolism through the "gut microbiota-estrogen axis," which could play an important role in perimenopausal symptoms.

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effectiveness and safety of Jinfeng Pill in women with perimenopausal syndrome. Eligible participants will be randomly assigned to receive either Jinfeng Pill or a placebo for 12 weeks. Researchers will assess changes in menopausal symptoms, mood, sleep, and quality of life using standardized questionnaires and laboratory tests.

In addition, the study will explore how Jinfeng Pill may regulate gut microbiota, β-glucuronidase (β-GUS) activity, short-chain fatty acids (SCFAs), inflammatory factors, and estrogen-related indicators. The findings may provide new evidence for the clinical use of traditional Chinese medicine in the treatment of perimenopausal syndrome and help clarify its underlying biological mechanisms.

02

Conditions studied

  • Perimenopausal Syndrome

Keywords

  • Perimenopausal Syndrome
  • Jinfeng Pill
03

In context

Lead sponsor

Tongji Hospital is the lead sponsor of 392 studies on the registry; 213 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients aged 45-55 years;
  2. Menstrual disorders (prolonged menstrual cycle or hypomenorrhea) lasting for more than 3 months, or amenorrhea for 2-12 months;
  3. Presence of vasomotor symptoms (hot flashes, sweating), somatic symptoms (insomnia, fatigue, headache, paresthesia), psychological symptoms (anxiety, depression), or urogenital symptoms (dyspareunia, vaginal dryness, urinary tract infection);
  4. Serum follicle-stimulating hormone (FSH) > 10 IU/L, or decreased estradiol (E2) levels;
  5. No use of HRT or other medications for perimenopausal symptoms in the past 2 months;
  6. Intact uterus and bilateral adnexa, not surgically removed;
  7. Voluntary participation and signing of ;
  8. Modified Kupperman Index (KI score) ≥ 6, indicating mild or above symptoms.

Exclusion criteria

Exclusion Criteria:

  1. Does not meet the inclusion criteria listed above;
  2. Ovarian , ovarian or hysterectomy, premature ovarian failure, uterine fibroids ≥2 cm, severe breast hyperplasia;
  3. Acute gynecological infectious diseases or other acute infectious diseases;
  4. Severe liver or kidney dysfunction, or other serious systemic diseases;
  5. Use of hormonal drugs or traditional Chinese medicine for treatment in the past 2 months;
  6. Participation in other clinical trials;
  7. Patients who did not adhere to the treatment protocol or withdrew from the trial;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    Placebo group

    Placebo

    Drug: Placebo

  • Experimental
    Jinfeng Pill group

    Jinfeng Pill

    Drug: Jinfeng Pill

Interventions

  • DrugJinfeng Pill

    Jinfeng Pill

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. The modified Kupperman Index (KI)

    The total score of KI is 63. It includes 13 items related to peri-menopausal syndrome, and the severity score of each item ranges from 0 to 3. There were different basic score in each item: hot flashes and sweating = 4; Paresthesia, sleep disorders, nervousness, sexual complaints, urinary tract infection = 2; the other items = 1. Item score = basic score × severity score. Classification standard of disease condition: mild: symptom score \<13; moderate: symptom score 14-26; severe: symptom score \>27 points.

    Time frame: Week -1, Week 0, Week 4, Week 8, Week 12, Week 16

Secondary outcomes

  1. Hot flash scale (HFs)

    The severity of hot flash was evaluated using visual analog scale (0-10).The higher the value, the more severe the symptoms.

    Time frame: Week -1, Week 0, Week 4, Week 8, Week 12, Week 16

  2. Menopause-specific quality of life scale (MENQOL)

    MENQOL contains 27 questions related to vasomotor symptoms, psychological symptoms, physiological symptoms, and sexual life. A lower MENQOL score indicates PMPS has a less influence on life quality.

    Time frame: Week 0, Week 12, Week 16

  3. Hamilton depressive scale (HAMD)

    The items of HAMD are scored on a 5-level scale with 0-4 points, a few items is a 3-level scale with 0-2 points. A higher score indicates the more severe depression.

    Time frame: Week 0, Week 12, Week 16

  4. Hamilton anxiety scale (HAMA)

    HAMA contains 14 items related to a number of anxiety symptoms. Each of items is scored on a 5-level scale with 0-4 points. A higher score indicates the more severe anxiety.

    Time frame: Week 0, Week 12, Week 16

  5. Vaginal Health Index (VHI)

    The VHIS (Vaginal Health Index) comprises five assessment dimensions, each scored from 1 to 5 points, for a total of 25 points. A higher total score indicates better vaginal health, while a total score below 15 points suggests vaginal atrophy.

    Time frame: Week 0, Week 12

  6. TCM Syndrome Score Scale

    Symptom severity will be graded according to the Guiding Principles for Clinical Research of New Chinese Medicines for eight TCM-specific symptom domains (hot flushes and sweating, menstrual irregularity, irritability, dizziness and headache, lumbar and knee soreness, insomnia with vivid dreaming, hypochondriac pain with bitter taste, and vaginal dryness), each rated 0-3 (absent/mild/moderate/severe). The total score is 24 points, with higher scores indicating more severe symptoms.

    Time frame: Week 0, Week 12

  7. Serum levels of sex hormones (E2, FSH, LH) and estrogen metabolites (2-OHE1,16α-OHE1)

    Serum E2, FSH, and LH will be quantified by enzyme-linked immunosorbent assay (ELISA). Estrogen metabolites - 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16α-OHE1) - will be determined by liquid chromatography-mass spectrometry (LC-MS).

    Time frame: Week 0, Week 12

  8. Serum inflammatory factors (IL-6, TNF-α)

    Serum concentrations of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) will be measured by ELISA

    Time frame: Week 0, Week 12

  9. Intestinal microbiota β-GUS enzyme activity

    β-GUS activity will be determined spectrophotometrically via the enzymatic hydrolysis of p-nitrophenyl-β-D-glucuronide (pNPG) to p-nitrophenol (pNP), quantified by absorbance at 405 nm.

    Time frame: Week 0, Week 12

  10. Short-Chain Fatty Acids (SCFAs)

    Faecal concentrations of acetic acid, propionic acid, and butyric acid will be determined by gas chromatography.

    Time frame: Week 0, Week 12

  11. Gut Microbiota Analysis

    Faecal samples will be collected at baseline and week 12. Participants will provide ≥5 mg of stool into a sterile collection tube, which will be immediately snap-frozen in liquid nitrogen and stored at -80°C pending analysis. Bacterial genomic DNA will be extracted using the QIAamp Swab DNA Kit (QIAGEN). The V3-V4 hypervariable regions of the 16S rRNA gene will be amplified by PCR and sequenced on the Illumina NextSeq 2000 platform.

    Time frame: Week 0, Week 12

07

Study locations

3 of 3 sites recruiting
  • Hubei Maternal and Child Health Hospital,Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
    Recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
    Recruiting
  • Wuhan Children's Hospital (Wuhan Maternal and Child Health Hospital),Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
    Recruiting
08

References and documents

Publications

  • Wu X, Zhou L, Hu J, Tian M, Liu S, Song K, Song Y, Xu X. Efficacy, safety and mechanism of Jinfeng pill in the treatment of perimenopausal syndrome: A protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Contemp Clin Trials Commun. 2026 Oct 26;54:101704. doi: 10.1016/j.conctc.2026.101704. eCollection 2026 Dec. PubMed 42999709 ↗

Individual participant data

Plan to share: No — Protecting participant privacy and data security.To consider potential data needs, please contact authorized researchers.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for May 2028, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 26, 2026
StartActual
May 10, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42999709 ↗
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42999709 ↗
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07606755
Lead sponsor
Tongji Hospital
Responsible party
Xiaohu Xu (Clinical Professor, Tongji Hospital) — Principal investigator
First posted
May 26, 2026
Start date
May 10, 2026
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Xiaohu Xu
Contact
hermanxu@163.com
+8613006111902

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion